12/15/2022 The Ministry of Health of the Russian Federation issued a license for the drug "Dimolegin"

On December 14, 2022, the Ministry of Health of the Russian Federation adopted Decision No. 25-5-4222291/ЧС/РЛП/1 on the state registration of a medicinal product for medical use "Dimolegin".

The drug Dimolegin received a temporary registration certificate of the Ministry of Health of the Russian Federation No. ЛП-008704, valid until 01.01.2024 for use as a means of preventing thrombotic complications in patients with COVID-19.

Thus, for the first time, the original Russian drug enters into competition with the drugs of pharmaceutical giants that fully occupy the Russian market of direct oral anticoagulants in the amount of 61.5 billion rubles (2021).

From our point of view, this is the most important event on the scale of the Russian pharmaceutical industry over the past 30 years.